ACADIA Pharmaceuticals, Inc. (ACAD) Announces Election of Stephen R. Biggar to its Board of Directors

ACADIA Pharmaceuticals, Inc. (ACAD) Announces Election of Stephen R. Biggar to its Board of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a vacancy on ACADIA's board and serve as a Class II director. The terms of the Class II directors will expire at the annual meeting of stockholders in 2015.

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.